Clinical Trials in Europe: Key Trends and Issues – Lung Cancer Europe
Lung Cancer Europe posted on LinkedIn:
“Clinical Trials in Europe: Key Trends and Issues.
- Globally clinical trials have increased by 38% over the past 10 years. However, Europe’s share of these trials has dropped by half.
- Some 70% of all lung cancer trials since 1999 have taken place in China, US and Japan even though Europe has the poorest lung cancer outcomes (incidence/mortality) in the world.
Access to clinical trials is critically important for people with lung cancer. In Europe, access to trials is highly inequitable and is worse in countries with higher disease burden and lower income levels.
Moreover, recruitment of participants remains slow and lacks diversity when compared to clinical trial leaders like the US.
As Europe is falling behind in the number of clinical trials, participants’ access to trials and new medicines will follow this trend.
Urgent policy action as well as investment is needed to course-correct.
We will present more findings on this issue tomorrow and Friday as well as our CALL TO ACTION.
This Policy Brief was prepared by Talha Jalal, LuCE’s EU Policy and Engagement Advisor, with contributions from Chiara Antoniani, LuCE’s EU Project Manager.
For more information, please email [email protected].”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023